Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) (MITOTARGET)

This study has been completed.
Sponsor:
Collaborator:
European Commission
Information provided by (Responsible Party):
Trophos
ClinicalTrials.gov Identifier:
NCT00868166
First received: March 23, 2009
Last updated: March 27, 2012
Last verified: March 2012
  Purpose

The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as compared to placebo, assessed by the 18-month survival rate.


Condition Intervention Phase
Amyotrophic Lateral Sclerosis
Drug: Olesoxime
Drug: Placebo Comparator
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole

Resource links provided by NLM:


Further study details as provided by Trophos:

Primary Outcome Measures:
  • The primary outcome measure will be the overall 18-month survival rate. [ Time Frame: Survival will be calculated from the date of randomization until the date of death or last follow-up censored at 18 months (548 days). ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Survival without occurrence of tracheostomy, chronic IV or NIV defined as >23h of NIV daily for 14 consecutive days. [ Time Frame: Time to failure will be defined as the time from randomization to the time of the first event to consider (Tracheostomy, IV or NIV) ] [ Designated as safety issue: Yes ]
  • Total score of the 48-point ALS Functional Rating Scale Revised, with a focus on the 9-month assessment [ Time Frame: Inclusion, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 15 and Month 18 ] [ Designated as safety issue: No ]
  • Slow Vital Capacity (SVC) as a percentage of predicted SVC and survival with SVC >50% [ Time Frame: Screening, Inclusion, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15 and Month 18 ] [ Designated as safety issue: Yes ]
  • Total Score of Manual Muscle Testing of 34 muscle groups [ Time Frame: Inclusion, Month 3, Month 6, Month 9, Month 12, Month 15 and Month 18 ] [ Designated as safety issue: No ]
  • The single-item Mc Gill Quality of life scale [ Time Frame: Inclusion, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15 and Month 18 ] [ Designated as safety issue: No ]

Enrollment: 512
Study Start Date: April 2009
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TRO19622
2 Capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzole 50mg bid
Drug: Olesoxime
2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
Placebo Comparator: Control
2 Capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
Drug: Placebo Comparator
2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid

Detailed Description:

A stand alone treatment with TRO19622 is not acceptable for ethical reasons. Riluzole is an approved and widely used ALS treatment in the European community, in Japan and in the USA.

Therefore, in this study, TRO19622 will be assessed as add-on to riluzole in patients suffering from ALS.

At the start of the study, patients will be randomized to one of two groups : TRO19622 (330 mg QD or placebo (once a day).

Each treatment will be administered for 18 months under double-blind conditions. The product under evaluation will be administered to patients receiving the standard of care for ALS, including riluzole.

Riluzole dosage (50 mg bid) must be stable and well tolerated for at least one month prior to inclusion into the study.

After the double-blind period, open-label administration of TRO19622 will be allowed for safety and survival assessments and until efficacy results are available.

A separate open-label protocol will be written 6 months after the randomization of the last patient into the study.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with sporadic or familial Amyotrophic Lateral Sclerosis
  • Patients with a clinical diagnosis of laboratory-supported probable, probable, or definite ALS according to the modified El Escorial criteria8.
  • Have signed an Informed Consent to participate to the trial before any study related procedure has taken place.
  • Be of age >18 (exclusive) and < 80 years (inclusive).
  • If a female, not lactating, has a negative pregnancy test and agrees to use an effective method of birth control.
  • Onset of ALS Symptoms (weakness) for more than 6 months (inclusive) and less than 36 months(inclusive).
  • Slow vital capacity (SVC), measured three times, one of the measure being >/= 70% of that predicted.
  • Treated with riluzole at the stable dose of 50 mg bid for at least 30 days before enrolment.

Exclusion Criteria:

  • Tracheostomy, invasive ventilation, or non invasive positive pressure ventilation (NIPPV).
  • Gastrostomy.
  • Evidence of major psychiatric disorder or clinically evident dementia.
  • Diagnosis of a neurodegenerative disease in addition to ALS.
  • Have a current medication that could interfere with TRO19622 pharmacokinetics: tamoxifene.
  • Have current medications that could interfere with TRO19622 absorption such as ezetimibe, bile salts chelators (cholesteramine), fibrates, phytosterols, niacin (vitamin B3),fish oils. Have a current medication of lipid lowering agents other than statins.
  • Known hypersensitivity to any component of the study drug.
  • Patients with known intolerance or contra-indication to riluzole.
  • Have a recent history (within the previous 6 months) or current evidence of alcohol or drug abuse.
  • Have concurrent unstable disease involving any system eg, carcinoma other than basal cell carcinoma, any cardiac dysrhythmia, myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac insufficiency, angina symptoms, current symptoms of Coronary Artery Disease, or any other condition that in the opinion of the Investigator would make the patient unsuitable for study participation.

    . In Germany: Have any cardiac dysrhythmia, myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac insufficiency, angina symptoms, current symptoms of Coronary Artery Disease or any cardiovascular illness known or identified at the screening or inclusion visits, or have concurrent unstable disease involving any system eg, carcinoma other than basal cell carcinoma or any other condition that in the opinion of the Investigator would make the patient unsuitable for study participation.

  • Having a baseline QTc (Bazett) > 450 msec for males and > 470 msec for females.
  • Patients with known hepatitis B/C or HIV positive serology.
  • Be pregnant female or lactating.
  • Have renal impairment defined as blood creatinine > 1:5 X upper limit of normal.
  • Have hepatic impairment and/or liver enzymes (ALAT or ASAT) > 3 X ULN.
  • Hemostasis disorders or current treatment with oral anticoagulants.
  • Be possibly dependent on the Investigator or the Sponsor (eg, including, but not limited to, affiliated employee).
  • Participated in any other investigational drug or therapy study with a non approved medication, within the previous 3 months.
  • Patients without Social Security Insurance (France).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00868166

Locations
Belgium
University Hospital Gasthuisberg - Dept Neurology - Herestraat 49
Leuven, Belgium, 3000
France
HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel
Bron Cedex, France, 69677
CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement
Lille, France, 59037
Centre SLA Limoges - Service de Neurologie
Limoges, France, 87042
Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires
Marseille, France, 13005
Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac
Montpellier, France, 34295
CHU de Nice - Hôpital de l'Archet 1 - Centre de Référence pour les Maladies Neuromusculaires et la SLA
Nice, France, 06202
Groupe Hospitalier PITIE-SALPETRIERE - Fédération des Maladies du Système Nerveux
Paris, France, 75013
Germany
Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz für ALS und andere Motoeneuronenerkrankungen
Berlin, Germany, 13353
Universitätsklinik und Poliklinik für Neurologie - Martin-Luther-Universität Halle-Wittenberg
Halle, Germany, 06097
Neurologische Klinik Medizinische Hochschule
Hannover, Germany, D-30623
Universitäts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik
Ulm, Germany, 89081
Spain
Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10
Madrid, Spain, 28029
United Kingdom
King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry
London, United Kingdom, SE58AF
Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences
Sheffield, United Kingdom, S10 2RX
Sponsors and Collaborators
Trophos
European Commission
Investigators
Principal Investigator: Vincent Meininger, MD, PhD Groupe Hospitalier Pitie-Salpetriere
  More Information

No publications provided

Responsible Party: Trophos
ClinicalTrials.gov Identifier: NCT00868166     History of Changes
Other Study ID Numbers: TRO19622 CL E Q 1015-1, EudraCT Number:2008-007320-25
Study First Received: March 23, 2009
Last Updated: March 27, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Belgium: Federal Agency for Medicinal Products and Health Products
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Spain: Spanish Agency of Medicines

Keywords provided by Trophos:
Amyotrophic Lateral Sclerosis
TRO19622
Trophos

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Sclerosis
Motor Neuron Disease
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
TDP-43 Proteinopathies
Neuromuscular Diseases
Proteostasis Deficiencies
Metabolic Diseases
Pathologic Processes
Riluzole
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Neuroprotective Agents
Protective Agents
Central Nervous System Agents
Therapeutic Uses
Anticonvulsants

ClinicalTrials.gov processed this record on July 26, 2014